Published Date: 05 Apr 2023
A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma
2.
Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer
3.
Higher Binge Drinking Rates Linked to New Cannabis Laws.
4.
Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC
5.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
3.
ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring
4.
The Immune Revolution: Neoantigen Vaccines and the Dawn of Personalized Cancer Therapy in 2025
5.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
3.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
5.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation